Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Transcription factors are believed to have a dominant role in acute myeloid leukemia (AML). This idea is supported by analysis of gene-knockout mice, which uncovered crucial roles of several transcription factors in normal hematopoiesis, and of individuals with leukemia, in whom transcription factors are frequently downregulated or mutated. However, analysis of knockout animals has not shown a direct link between abrogated transcription factors and the pathogenesis of AML. Sfpi1, encoding the lineage-specific transcription factor PU.1, is indispensable for normal myeloid and lymphoid development. We found that mice carrying hypomorphic Sfpi1 alleles that reduce PU.1 expression to 20% of normal levels, unlike mice carrying homo- or heterozygous deletions of Sfpi1, developed AML. Unlike complete or 50% loss, 80% loss of PU.1 induced a precancerous state characterized by accumulation of an abnormal precursor pool retaining responsiveness to G-CSF with disruption of M- and GM-CSF pathways. Malignant transformation was associated with a high frequency of clonal chromosomal changes. Retroviral restoration of PU.1 expression rescued myeloid differentiation of mutant progenitors and AML blasts. These results suggest that tightly graded reduction, rather than complete loss, of a lineage-indispensable transcription factor can induce AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preleukemic states (e.g., MDS), where PU.1 downregulation permits clonal expansion 33-35”
From USP7 sustains hematopoietic stem cell homeostasis partially via PU.1 stabilization (2026) · cites this paper as [33]
In the citing paper
“In mice, a decrease in Pu.1-mediated differentiation gene activation causes leukemia.22”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [22]
In the citing paper
“Studies in murine models of AML with decreased levels of PU.1 showed an elevated expression of c-Myc.28”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [28]
In the citing paper
“A reduction in PU.1 expression and activity is commonly seen in mouse and human cases of AML.[28][29][30]”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [28]
In the citing paper
“Although loss or near-complete loss of the hematopoietic transcription factor PU.1 induces acute myeloid leukemia (AML) in mice”
From Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia (2015) · cites this paper as [9]
19 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617 · cited 1×
“We could not separate mutant progenitors into distinct common myeloid progenitor, myeloid-erythroid progenitor and granulocyte-macrophage progenitor subpopulation”
BackgroundSelf-citationOkuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856 · cited 1×
“Like mice deficient in other transcription factors implicated in human AM”
BackgroundThe c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
Scott, E. W., Simon, M. C., Anastasi, J., & Singh, H. (1994) · Science · doi:10.1126/science.8079170 · Cited by 1,532
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289 · cited 1×
“F331 Spleen 39,X,-Y[6]/40,idem,+15[2]/41,XY,+15[2]”
Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130
An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination
Meyers, E. N., Lewandoski, M., & Martin, G. R. (1998) · Nature Genetics · doi:10.1038/ng0298-136 · Cited by 1,031 · cited 1×
“We released a FRT -PGK neo - FRT resistance cassette from pK-11 (ref”
MethodZhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“Like mice deficient in other transcription factors implicated in human AM”
BackgroundSelf-citationPabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901
Self-citationReversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Research works printed but not linked: 2
- Iwasaki-Arai, J. et al. C/EBPα deficiency in hematopoiesis induces accumulation of non-malignant myeloblasts mimicking acute myelogenous leukemia. Blood 100, 61a (2002).
- Duprez, E. et al. PU.1 deficiency blocks the production of Common Myeloid and Common Lymphoid Progenitors in both adult and fetal liver myelopoiesis. Blood 100, 61a (2002).
Cited by
Items 301–400 of 518
Fukuchi, Y., Ito, M., Shibata, F., Kitamura, T., & Nakajima, H. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0320 · Cited by 20
Preanalytical mRNA Stabilization of Whole Bone Marrow Samples
Langebrake, C., Günther, K., Lauber, J., & Reinhardt, D. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.078592 · Cited by 23
Pharmacogenetics of Alkylator-Associated Acute Myeloid Leukemia
Knoche, E., McLeod, H. L., & Graubert, T. A. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.5.719 · Cited by 19
Jung, M. M., Shen, S., Botten, G. A., Olender, T., Katsumura, K. R., Johnson, K. D., Soukup, A. A., Liu, P., Zhang, Q., Jensvold, Z. D., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162685 · Cited by 19
TIP60 is required for tumorigenesis in non‐small cell lung cancer
Shibahara, D., Akanuma, N., Kobayashi, I. S., Heo, E., Ando, M., Fujii, M., Jiang, F., Prin, P. N., Pan, G., Wong, K., et al. (2023) · Cancer Science · doi:10.1111/cas.15785 · Cited by 21
Self-citationTemporal autoregulation during human PU.1 locus SubTAD formation
Schuetzmann, D., Walter, C., van Riel, B., Kruse, S., König, T., Erdmann, T., Tönges, A., Bindels, E. M., Weilemann, A., Gebhard, C., et al. (2018) · Blood · doi:10.1182/blood-2018-02-834721 · Cited by 20
Self-citationMyeloid leukemia with transdifferentiation plasticity developing from T‐cell progenitors
Riemke, P., Czéh, M., Fischer, J., Walter, C., Ghani, S., Zepper, M., Agelopoulos, K., Lettermann, S., Gebhardt, M. L., Mah, N., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201693927 · Cited by 20
“MSCV-IRES-GFP-IRES-PU.1 was described in Rosenbauer et al (2004) and MSCV-IRES-GFP in Huntly et al (2004).”
Self-citationEnforced GFI1 expression impedes human and murine leukemic cell growth
Hönes, J. M., Thivakaran, A., Botezatu, L., Patnana, P. K., Castro, S. V. D. C., Al-Matary, Y. S., Schütte, J., Fischer, K. B. I., Vaßen, L., Görgens, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15866-9 · Cited by 22
Fusion-protein truncation provides new insights into leukemogenesis
Hess, J. L., & Hug, B. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407898101 · Cited by 19
DNA methylation-mediated silencing of PU.1 in leukemia cells resistant to cell differentiation
Fernández-Nestosa, M. J., Monturus, E., Sánchez, Z., Torres, F. S., Fernández, A. F., Fraga, M. F., Hernández, P., Schvartzman, J. B., & Krimer, D. B. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-392 · Cited by 20
“…ttccatggtagtgctagcctttctccctcccagccccagtttcctctgggcaggggcctggccccctgtcttccca gggctgccctttgagaaccacctgccccagccggccagagacttcctgtagcgcaagagatttatgcaaacgggct ggggcggtgatgtcaccccaaggggactatctcccagtggcaggcccttcgataaaatcaggaacttgtgctggcc…”
A role for ATP Citrate Lyase in cell cycle regulation during myeloid differentiation
Rhee, J., Solomon, L. A., & DeKoter, R. P. (2019) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2019.02.006 · Cited by 18
t(3;21)(q22;q22) leading to truncation of the RYK gene in atypical chronic myeloid leukemia
Micci, F., Panagopoulos, I., Haugom, L., Andersen, H. K., Tjønnfjord, G. E., Beiske, K., & Heim, S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.12.016 · Cited by 18
Guo, H. W., Barberi, T. J., Suresh, R., & Friedman, A. D. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800244 · Cited by 18
“1(kd/kd) mice (11), kindly provided by D.”
Xu, J., Patrick, B., & Jaiswal, A. K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.495580 · Cited by 20
Zou, D., Yang, X., Tan, Y., Wang, P., Zhu, X., Yang, W., Jia, X., Zhang, J., & Wang, K. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.09.012 · Cited by 19
LSD1 inhibition modulates transcription factor networks in myeloid malignancies
Hartung, E. E., Singh, K., & Berg, T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1149754 · Cited by 19
“1 knock down animals develop hypercellularity of the liver and spleen due to expansion of myeloblasts, and greatly accumulate immature myeloid cells (cKit Mac-1 GR-1) (60).”
BackgroundInfluentialIdentification of annexin 1 as a PU.1 target gene in leukemia cells
Iseki, Y., Imoto, A., Okazaki, T., Harigae, H., & Takahashi, S. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.04.010 · Cited by 28
“1 xpression to 20% of its normal levels were reported to develop ML [3].”
BackgroundKras mutations and PU.1 promoter methylation are new pathways in murine radiation-induced AML
O’Brien, G., Cruz-Garcia, L., Żyła, J., Brown, N., Finnon, R., Polańska, J., & Badie, C. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz175 · Cited by 19
“Previous work has shown that reduced expression of Sfpi1 in haematopoietic stem cells and progenitors down to 20% of wild-type levels will result in the development of AML within 3–8 months (30).”
BackgroundMahmoodi, S. H., Aghdam, R., & Eslahchi, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-87074-5 · Cited by 19
Sive, J. I., Basilico, S., Hannah, R., Kinston, S. J., Calero-Nieto, F. J., & Göttgens, B. (2016) · Leukemia · doi:10.1038/leu.2015.172 · Cited by 17
Mouse Models of Radiation-Induced Cancers
Rivina, L., & Schiestl, R. H. (2013) · Advances in genetics · doi:10.1016/b978-0-12-407703-4.00003-7 · Cited by 18
PU.1 and CEBPA expression in acute myeloid leukemia
D’Alò, F., Ruscio, A. D., Guidi, F., Fabiani, E., Greco, M., Rumi, C., Hohaus, S., Voso, M. T., & Leone, G. G. M. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.01.007 · Cited by 17
Guidi, R., Wedeles, C. J., & Wilson, M. S. (2020) · Non-Coding RNA · doi:10.3390/ncrna6010010 · Cited by 19
Olme, C.-H., Finnon, R., Brown, N., Kabacik, S., Bouffler, S. D., & Badie, C. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.05.019 · Cited by 18
Acute myeloid leukemia with expanded erythropoiesis
Porwit‐MacDonald, A., & Vardiman, J. (2011) · Haematologica · doi:10.3324/haematol.2011.050526 · Cited by 17
“1 levels develop erythroleukemias with a high rate of aberrant karyotypes.(19,20)”
BackgroundPU.1 promotes cell cycle exit in the murine myeloid lineage associated with downregulation of E2F1
Ziliotto, R. G., Gruca, M. R., Podder, S., Noel, G., Ogle, C. K., Hess, D. A., & DeKoter, R. P. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.11.011 · Cited by 16
“1 is sufficient to induce AML [15,16].”
BackgroundBarakat, D. J., Suresh, R., Barberi, T. J., Pienta, K. J., Simons, B. W., & Friedman, A. D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191188 · Cited by 17
Olme, C.-H., Brown, N., Finnon, R., Bouffler, S. D., & Badie, C. (2013) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2013.04.018 · Cited by 17
Seshire, A., Rößiger, T., Frech, M., Beez, S., Hagemeyer, H., & Puccetti, E. (2011) · Leukemia · doi:10.1038/leu.2011.331 · Cited by 17
Steffen, L. S., Bacher, J., Peng, Y., Le, P. N., Ding, L.-H., Genik, P. C., Ray, F. A., Bedford, J. S., Fallgren, C. M., Bailey, S. M., et al. (2012) · Mutagenesis · doi:10.1093/mutage/ges055 · Cited by 18
Hirako, N., Nakano, H., & Takahashi, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103282 · Cited by 19
“Mice carrying hypomorphic SPI1 alleles that reduce PU.1 expression to 20% of its normal levels exhibit blockade of myeloid differentiation, leading to the development of acute myeloid leukemia (AML) [11].”
BackgroundInfluentialEndo, S., Amano, M., Nishimura, N., Ueno, N., Ueno, S., Yuki, H., Fujiwara, S., Wada, N. A., Hirata, S., Hata, H., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.11.116 · Cited by 16
Self-citationThe histone demethylase Jmjd3 regulates zebrafish myeloid development by promoting spi1 expression
Yu, S., Zhu, K.-Y., Zhang, F., Wang, J., Yuan, H., Chen, Y., Jin, Y., Dong, M., Wang, L., Jia, X., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2017.12.009 · Cited by 18
“Likewise, a graded reduction of Spi1 to 20% of the wild type level induces AML in mice [63].”
BackgroundBehzad, M. M., Shahrabi, S., Jaseb, K., Bertacchini, J., Ketabchi, N., & Saki, N. (2018) · Biochemical Genetics · doi:10.1007/s10528-018-9841-1 · Cited by 17
“The PU.1 protein is an essential regulator of proliferation during the myeloid progenitor cell development that is subjected to aberrant methylation in a variety of hematological malignancies (Rosenbauer et al. 2004; Yang et al. 2012).”
BackgroundCore-binding factor leukemia hijacks the T-cell–prone PU.1 antisense promoter
van der Kouwe, E., Heller, G., Czibere, A. G., Pulikkan, J. A., Agreiter, C., Castilla, L. H., Delwel, R., Ruscio, A. D., Ebralidze, A. K., Forte, M., et al. (2021) · Blood · doi:10.1182/blood.2020008971 · Cited by 18
Self-citationPU.1 expression is restored upon treatment of chronic myeloid leukemia patients
Albajar, M., Gutierrez, P., Richard, C., Rosa‐Garrido, M., Gómez‐Casares, M. T., Steegmann, J. L., León, J., & Delgado, M. D. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.05.024 · Cited by 18
Multiple DNA-binding modes for the ETS family transcription factor PU.1
Esaki, S., Evich, M. G., Erlitzki, N., Germann, M. W., & Poon, G. M. K. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.798207 · Cited by 20
Xu, J., & Jaiswal, A. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.387738 · Cited by 15
RetractedReceptor Tyrosine Kinase Alterations in AML – Biology and Therapy
Stirewalt, D. L., & Meshinchi, S. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-69259-3_6 · Cited by 19
PU.1 immortalizes hematopoietic progenitors in a GM-CSF-dependent manner
Houston, I. B., Huang, K. J., Jennings, S. R., & DeKoter, R. P. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2006.11.003 · Cited by 16
β-Alanine and N-terminal cationic substituents affect polyamide–DNA binding
Liu, B., Wang, S., Aston, K. W., Koeller, K. J., Kermani, S. F. H., Castañeda, C. H., Scuderi, M. J., Luo, R., Bashkin, J. K., & Wilson, W. D. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02513k · Cited by 14
Qian, M., Jin, W. Y., Zhu, X., Jia, X., Yang, X., Du, Y., Wang, K., & Zhang, J. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-25 · Cited by 14
“1 in hematopoietic cells causes the blockage of cell differentiation [44] and restoration of PU.”
BackgroundChasing leukemia differentiation through induction therapy, relapse and transplantation
Saultz, J. N., & Tyner, J. W. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101000 · Cited by 15
Zhao, M. L., Duan, X.-F., Wen, D., & Chen, G. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.03.024 · Cited by 15
Aoyama, S., Nakano, H., Danbara, M., Higashihara, M., Harigae, H., & Takahashi, S. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.03.071 · Cited by 14
Mouse Models for Efficacy Testing of Agents against Radiation Carcinogenesis — A Literature Review
Rivina, L., & Schiestl, R. H. (2012) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10010107 · Cited by 16
“1 (expressing ~20% of WT levels) induces AML in mice by 3–8 months of age [91] and myeloid leukemia when inactivated in adult mice [92].”
BackgroundBrown, N., Finnon, R., Bulman, R. A., Finnon, P., Moody, J. C., Bouffler, S. D., & Badie, C. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.06.015 · Cited by 15
c-FMS chromatin structure and expression in normal and leukaemic myelopoiesis
Follows, G., Tagoh, H., Richards, S. J., Melnik, S., Dickinson, H., de Wynter, E., Lefevre, P., Morgan, G. J., & Bonifer, C. (2005) · Oncogene · doi:10.1038/sj.onc.1208655 · Cited by 13
Moreau-Gachelin, F. (2006) · PubMed · Cited by 18
Liu, T., Wang, T., Qi, L., Liu, Y., Shan, M., Wang, F., Fang, Y., Liu, S., Wen, L., Chen, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-54860-4 · Cited by 13
Chiriches, C., Nicolaisen, N., Wieske, M., Elhaddad, H., Mehmetbeyoğlu, E., Alvares, C. L., Becher, D., Hole, P. S., Ottmann, O. G., & Ruthardt, M. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010463 · Cited by 12
“These differences can influence functionality, as reported for PU.1, where a slight reduction of its functionality is responsible for the induction of leukemia [44].”
BackgroundFleenor, C. J., Higa, K. C., Weil, M. M., & DeGregori, J. V. (2015) · Radiation Research · doi:10.1667/rr14147.1 · Cited by 13
“1 develop AML disease within months after irradiation (51, 52).”
Zasłona, Z., Scruggs, A. M., Peters-Golden, M. L., & Huang, S. K. (2016) · Immunology · doi:10.1111/imm.12641 · Cited by 13
RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML
Hyde, R. K., Liu, P., & Friedman, A. D. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_17 · Cited by 13
Dimberg, A., Kårehed, K., Nilsson, K., & Oberg, F. G. (2006) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2006.01827.x · Cited by 13
PML is a key component for the differentiation of myeloid progenitor cells to macrophages
Khalfin-Rabinovich, Y., Weinstein, A., & Levi, B.-Z. (2011) · International Immunology · doi:10.1093/intimm/dxr004 · Cited by 13
Genome-Wide Approaches to Defining Macrophage Identity and Function
Fonseca, G. J., Seidman, J. S., & Glass, C. K. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0039-2016 · Cited by 13
“Indeed, blocks in differentiation resulting from loss of PU.1 result in leukemic transformation of myeloid cells (68, 69).”
BackgroundBento, L. C., Bacal, N. S., Rocha, F. A., Severino, P., & Marti, L. C. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900328 · Cited by 12
“Transcription factors work either synergistically or antagonistically (31–33), suggesting that absolute levels (34), as well as specific combinations of them (35), are needed for normal hematopoietic differentiation.”
BackgroundUchiumi, F., Enokida, K., Shiraishi, T., Masumi, A., & Tanuma, S.-I. (2010) · Gene · doi:10.1016/j.gene.2010.04.014 · Cited by 11
A STATus report on DC development
Li, H. S., & Watowich, S. S. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0212052 · Cited by 13
DNMT1 Deficiency Impacts on Plasmacytoid Dendritic Cells in Homeostasis and Autoimmune Disease
Czéh, M., Stäble, S., Krämer, S., Tepe, L., Talyan, S., Carrelha, J., Meng, Y., Heitplatz, B., Schwabenland, M., Milsom, M. D., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100624 · Cited by 12
Self-citationOgbonna, E. N., Paul, A., Terrell, J. R., Fang, Z., Chen, C., Poon, G. M. K., Boykin, D. W., & Wilson, W. D. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116861 · Cited by 12
Yamada, T., Shimizu, T., Suzuki, M., Kihara‐Negishi, F., Nanashima, N., Sakurai, T., Yang, F., Akita, M., Oikawa, T., & Tsuchida, S. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.11.005 · Cited by 12
One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying them
Knox, A. V. C., Cominsky, L. Y., Sun, D., Cabrera, E. C., Nolan, B. E., Ofray, E., Benetti, E., Visconti, C., Barzaghi, F., Rosenzweig, S. D., et al. (2025) · Blood · doi:10.1182/blood.2024026683 · Cited by 11
Pin1‐Mediated Prolyl Isomerization of Runx1 Affects PU.1 Expression in Pre‐Monocytes
Islam, R., Yoon, W., Woo, K. M., Baek, J., & Ryoo, H. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24462 · Cited by 11
“The development of mature blood cells from hematopoietic precursors requires cooperation between additional transcription factors and Runx1; these cooperating factors include the ETS-family member PU.1 and GATA1 (McKercher et al., 1996; Scott et al., 1997).”
BackgroundGenistein Protects Hematopoietic Stem Cells against G-CSF–Induced DNA Damage
Souza, L. R., Silva, E., Calloway, E., Küçük, Ö., Rossi, M. R., & McLemore, M. L. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0295 · Cited by 10
From Genotype to Phenotype: How Enhancers Control Gene Expression and Cell Identity in Hematopoiesis
Mulet‐Lazaro, R., & Delwel, R. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000969 · Cited by 11
“225,226 Nonetheless, the fact that loss of the −15 kb enhancer affects all blood lineages indicates it is a general hematopoietic enhancer.”
BackgroundSuzuki, S., Nakano, H., & Takahashi, S. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.007 · Cited by 10
Nouri, M., Deezagi, A., & Ebrahimi, M. (2016) · Annals of Hematology · doi:10.1007/s00277-015-2583-9 · Cited by 10
Goto, H., Kariya, R., Kudo, E., Okuno, Y., Ueda, K., Katano, H., & Okada, S. (2017) · Oncogene · doi:10.1038/onc.2017.138 · Cited by 10
Self-citationRare Hematological Malignancies
Ansell, S. M. (2007) · Springer eBooks · doi:10.1007/978-0-387-73744-7 · Cited by 11
Stirewalt, D. L. (2004) · Nature Genetics · doi:10.1038/ng0604-550 · Cited by 10
Blood stem cell PU.1 upregulation is a consequence of differentiation without fast autoregulation
Ahmed, N., Etzrodt, M., Dettinger, P., Kull, T., Loeffler, D., Hoppe, P. S., Chavez, J. S., Zhang, Y., Camargo Ortega, G., Hilsenbeck, O., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20202490 · Cited by 9
mTORC2 orchestrates monocytic and granulocytic lineage commitment by an ATF5-mediated pathway
Zhao, Y., Zhao, C., Guo, H., Zhang, Z., Xu, H., Shi, M., Xu, Y., Dong, W., & Zhao, Y. (2023) · iScience · doi:10.1016/j.isci.2023.107540 · Cited by 9
“Increased PU.1 activity favors monocytic commitment of GMPs.43,44 Early growth response factor 1 (Egr-1), Egr-2, AP-1, MafB/c:Fos complexes, CCAAT/enhancer-binding protein b (C/EBPb), and Egr-1/ NGFI-A-binding protein 2 (Nab2) complexes (A) Network analysis of AKT-regulated genes and differential gene enrichment trans…”
BackgroundInfluentialMinaeva, M., Domingo, J., Rentzsch, P., & Lappalainen, T. (2025) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqae178 · Cited by 10
FLT3-driven redox-modulation of Ezrin regulates leukaemic cell migration
Corcoran, A., & Cotter, T. G. (2012) · Free Radical Research · doi:10.3109/10715762.2012.733385 · Cited by 10
Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children
Clark, J., Berman, J. N., & Look, A. T. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3431-5.00011-x · Cited by 10
Korczmar, E., Bookstaver, A. K., Ober, E., Goldfarb, A. N., Tenen, D. G., & Trinh, B. Q. (2024) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1602010 · Cited by 9
“Low PU.1 expression is needed for granulocytic and B cells [5,11,19].”
BackgroundInfluentialSelf-citationFederzoni, E. A., Humbert, M., Valk, P. J. M., Behre, G., Leibundgut, E. O., Torbett, B. E., Fey, M. F., & Tschan, M. P. (2012) · British Journal of Haematology · doi:10.1111/bjh.12170 · Cited by 8
Tumor suppressor gene inactivation in myeloid malignancies
Wong, J. C. Y., Beau, M. M. L., & Shannon, K. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.09.001 · Cited by 9
Introduction and Classification of Leukemias
Brown, G. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0810-4_1 · Cited by 11
Walter, M. J., Ries, R. E., Armstrong, J. R., Park, J. S., Mardis, E. R., & Ley, T. J. (2006) · Blood · doi:10.1182/blood-2006-07-037465 · Cited by 8
PU.1 is a tumor suppressor for B cell malignancies
Okuno, Y., & Yuki, H. (2012) · Oncotarget · doi:10.18632/oncotarget.800 · Cited by 8
Self-citationmiR-155 in Acute Myeloid Leukemia: Not Merely a Prognostic Marker?
Joyce, C. E., & Novina, C. D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3180 · Cited by 8
Leukemogenesis in HeterozygousPU.1Knockout Mice
Genik, P. C., Vyazunova, I., Steffen, L. S., Bacher, J. W., Bielefeldt‐Ohmann, H., McKercher, S. R., Ullrich, R. L., Fallgren, C. M., Weil, M. M., & Ray, F. A. (2014) · Radiation Research · doi:10.1667/rr13738.1 · Cited by 7
“Genomic DNA was amplified from 4 ng DNA with GoTaq Hot Start Colorless Master Mix (Promega) and 250 nM PCR primers (Exon 5a: 50-CTACCATGGCTGGGAGGAG-3 0 and 50-GACTCTAGCCCGCTCCAA-3 0; Exon 5b: 50-GACAGGCGAGGTGAAGAAAG-3 and 50-CCAGCTTTGGAAACATGCTC-3 0) on a Veriti 96-well fast thermal cycler (Applied Biosystems) with th…”
BackgroundMethodInfluentialPU.1, a Shared Transcriptional Regulator of Innate and Adaptive Immune Cell Fates
Singh, H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1595 · Cited by 7
“1 gene could also be shown to cause acute myeloid leukemia in mice (8).”
BackgroundPU.1 directly regulates retinoic acid-induced expression of RIG-G in leukemia cells
Gu, Z.-M., Liu, C., Wu, S.-F., Zhao, M. L., Xu, H.-Z., Liu, W., Zhou, H.-C., Chen, G., & Wu, Y. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.12.021 · Cited by 7
“1 expression leads to acute myeloid leukemias (AML) [4].”
BackgroundModulating DNA by polyamides to regulate transcription factor PU.1-DNA binding interactions
Liu, B., Bashkin, J. K., Poon, G. M. K., Wang, S., Wang, S., & Wilson, W. D. (2019) · Biochimie · doi:10.1016/j.biochi.2019.08.009 · Cited by 7
“1 expression to 20% of normal cell levels is reported to induce acute myeloid leukemia (AML) in mice, whereas a decrease to 50% of normal cell expression retains normal hematopoiesis [24, 25].”
BackgroundCombined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents
Bašová, P., Paszeková, H., Minařík, Ľ., Dluhošová, M., Burda, P., & Stopka, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126729 · Cited by 7
“1 expression levels were held at ~20% by the removal of the URE enhancer, which is required for promoter and URE self-stimulation [3].”
BackgroundInfluentialEpigenetic aberrations in myeloid malignancies (Review)
Takahashi, S. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1417 · Cited by 7
Mishra, S., 刘, J. 军. L., Chai, L., & Tenen, D. G. (2022) · PubMed · doi:10.1097/moh.0000000000000692 · Cited by 13
Self-citationUp a lymphoid blind alley: Does CALM/AF10 disturb Ikaros during leukemogenesis?
Greif, P. A., & Bohlander, S. K. (2011) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v2.i6.115 · Cited by 8
Qiu, K., Vu, D. C., Wang, L., Nguyen, N. N., Bookstaver, A. K., Sol‐Church, K., Li, H., Dinh, T. N., Goldfarb, A. N., Tenen, D. G., et al. (2024) · Epigenetics & Chromatin · doi:10.1186/s13072-024-00556-4 · Cited by 7
“Among PCREs, the URE has been demonstrated to be bifunctional as an enhancer in myeloid cells and a silencer in T cells [8, 16–18].”
BackgroundMethodInfluentialSelf-citationDual mechanism of inflammation sensing by the hematopoietic progenitor genome
Tran, V. L., Liu, P., Katsumura, K. R., Soukup, A. A., Kopp, A., Ahmad, Z. S., Mattina, A. E., Brand, M., Johnson, K. D., & Bresnick, E. H. (2025) · Science Advances · doi:10.1126/sciadv.adv3169 · Cited by 6
“Expression of Spi1 , encoding PU.1, is controlled by a − 14-kb enhancer [upstream regulatory element (URE)] ( 38 , 39 ).”
Pawlikowska, P., Delestré, L., Gregoricchio, S., Oppezzo, A., Esposito, M., Diop, M. K., Rosselli, F., & Guillouf, C. (2023) · Oncogene · doi:10.1038/s41388-023-02800-9 · Cited by 6
Zhou, J., Zhang, X., Wang, Y., & Guan, Y. (2015) · Oncology Letters · doi:10.3892/ol.2015.3404 · Cited by 7
“Dysregulation of PU.1 leads to loss of lineage development and leukemia in vitro and in vivo (9,26-28).”
Mouse Models of Human Blood Cancers: Basic Research and Pre-clinical Applications
Li, S. (2008) · Springer eBooks · doi:10.1007/978-0-387-69132-9 · Cited by 6
Hosokawa, H., Masuhara, K., & Koizumi, M. (2021) · BioEssays · doi:10.1002/bies.202000345 · Cited by 7
“1 can induce T cell leukemia; thus, its expression has to be regulated tightly.[14,38,39] However, molecular mechanisms underlying how PU.”
BackgroundMutations of the transcription factor PU.1 are not associated with acute lymphoblastic leukaemia
Mueller, B. U., Pabst, T., Hauser, P., Gilliland, G. D., Neuberg, D. S., & Tenen, D. G. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603198 · Cited by 7
Self-citationMartowicz, M. L., Grass, J. A., & Bresnick, E. H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605774200 · Cited by 6
Metadata
- Authors
- Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Dartmouth College (US)
- Corresponding author
- Tenen, Daniel G
- ORCID
- Venue
- Nature Genetics
- Published
- 2004-05-16
- Volume
- 36
- Issue
- 6
- Pages
- 624-630
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2060618743
- Cited by
- 506
- References
- 28
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 11 · 2023: 21 · 2022: 10 · 2021: 25 · 2020: 13 · 2019: 22 · 2018: 25 · 2017: 24 · 2016: 19 · 2015: 18 · 2014: 27 · 2013: 36 · 2012: 28
- FWCI
- 20.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Funders
- Dartmouth College
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- National Cancer Institute (P30CA023108)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- acute myeloid leukemia, PU.1, transcription factors, hypomorphic allele, myeloid development, myeloid differentiation, leukemogenesis
- MeSH terms
- Proto-Oncogene Protein Spi-1, Animals, Bone Marrow, Hematopoiesis, Humans, Karyotyping, Mice, Inbred C57BL, Mice, Mutant Strains, Mice, Transgenic, Proto-Oncogene Proteins, Spleen, Leukemia, Myeloid, Acute, Trans-Activators, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.